Carboplatin dosage

Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 7( 11) 1748-1756. 

A variety of other compounds have mechanisms of action that involve alkylation. These include procarbazine, dacarbazine, altretamine (hexamethylmelamine), cisplatin, and carboplatin. Dosages and major toxicities are listed in Table 55-2. 

The RT consisted of 45 Gy in 3 wk using 1.5 Gy bid concurrent with either cisplatin/etoposide or carboplatin/vindesine after the same drugs had been given alone at higher dosage. Acute toxicity was acceptable and treatment-related deaths were 9% or... 

Conventional dosages of carboplatin have been associated with the lowest risk of peripheral neuropathy (for example mild paresthesia) among the approved platinum compounds. It has been estimated that about 4-6% of patients who receive carboplatin develop a peripheral nenropathy. Patients over 65 years of age or patients pretreated with other neurotoxic agents may be at a slightly higher risk (61). 

Underlying risk factors, which predispose patients to more severe forms of myelosuppression, include lower initial blood cell counts, renal impairment, poor performance status, extensive prior chemotherapy, and advanced age. There is a strong correlation between carboplatin pharmacokinetics and the severity of myelo-suppressive adverse effects an AUC-adapted dosage of carboplatin is therefore highly recommended during conventional dose chemotherapy (22,23,155). 

Canetta R, Rozencweig M, Carter SK. Carboplatin the clinical spectrum to date. CancerTreat Rev. 1985 Sep 12 SuppI A 125-36 Egorin MJ,Van Echo DA,Tipping SJ, Olman EA, Whitacre MY,Thompson BW, Aisner J. Pharmacokinetics and dosage reduction of cis-diammine[1,1-cyclobutanedicarboxylato]platinum in patients with impaired renal function. Cancer Res. 1984 Nov 44[11] 5432-8... 

Van Warmerdam, L. J., Rodenhuis, S., ten Bokkel Huinink, W. W., Maes, R. A. and Beijnen, J. H., Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother. Pharmacol., 37(3), 266,1996. 

---